To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resistance mutations in HCV genotype 1-infected PI-naive individuals in Italy
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
International audienceBackground: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor...
HCV is ubiquitous. In 50% of all cases it causes chronic hepatitis that often evolves into liver cir...
To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resistance mutati...
OBJECTIVES: To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resi...
Objectives: Genetic variability in NS5A is associated with different levels of resistance to the cur...
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which i...
Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence acro...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
The aim of this study was to measure the frequency of natural mutations in hepatitis C virus (HCV) m...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
International audienceBackground: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor...
HCV is ubiquitous. In 50% of all cases it causes chronic hepatitis that often evolves into liver cir...
To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resistance mutati...
OBJECTIVES: To assess the prevalence of hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) resi...
Objectives: Genetic variability in NS5A is associated with different levels of resistance to the cur...
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which i...
Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence acro...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
The aim of this study was to measure the frequency of natural mutations in hepatitis C virus (HCV) m...
Several new direct-acting antiviral (DAA) drugs are being developed or are already approved for the ...
International audienceBackground: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor...
HCV is ubiquitous. In 50% of all cases it causes chronic hepatitis that often evolves into liver cir...